CONSUMER UNDERSTANDING OF THE MODIFIED RISK INFORMATION

Presented by: Alexander Persoskie, PhD Social Scientist, Division of Population Health Science Office of Science Center for Tobacco Products

Disclaimer: This is not a formal dissemination of information by FDA and does not represent Agency position or policy.



February 14, 2020

CENTER FOR TOBACCO PRODUCTS







Statutory requirements for public understanding of the modified risk information.



Background on U.S. public's misperceptions about nicotine.



Description of the proposed VLN[™] labeling and advertising.



Preliminary evaluation of applicant's studies related to understanding.



911 (g)(2) (B)(iii)

JNDERSTAN DI NG

Testing of actual consumer perception shows that, as the applicant proposes to label and market the product, **consumers will not be misled** into believing that the product:

- is or has been demonstrated to be less harmful; or
- presents or has been demonstrated to present less of a risk of disease than 1 or more other commercially marketed tobacco products.

The advertising/labeling enables the public to:

- comprehend the information concerning modified risk, and
- 911 (h)(1)

IDERSTANDING

- understand the relative significance of such information
 - in the context of total health, and
 - in relation to all tobacco-related diseases and health conditions.





Discuss whether the labeling enables consumers to accurately understand the following effects of using the products:

- Addiction risk
- Disease risks



 \mathcal{P} The proposed labeling and advertising submitted.

- P The applicant's studies:
 - Quantitative consumer perception study.
 - Qualitative consumer perception studies.

P Peer-reviewed studies of perceptions of nicotine and low nicotine content cigarettes.



FDA is evaluating consumer understanding, including whether the labeling would enable people to understand the following:




VLN[™] cigarettes are less addictive than other cigarettes and similarly addictive as NRT.




VLN[™] cigarettes have same disease risk as other cigarettes when smoked in the same way.

BACKGROUND: NICOTINE MISPERCEPTIONS

U.S. public has misperceptions about nicotine and very low nicotine content (VLNC) cigarettes.





1. Byron et al., 2018

Denlinger-Apte et al., 2017

6 February 14, 2020 | 22nd Century Group Inc., Modified Risk Tobacco Product Applications

FDA



PROPOSED LABELING



Proposed labeling for non-menthol product. Source: Section V – Labels, Labeling, and Advertising.

CENTER FOR TOBACCO PRODUCTS

PROPOSED ADVERTISING: EXAMPLE PRINT ADS





Source: Section V – VLN Marketing Outline.



Online study: Participants randomized to view VLN[™] or Marlboro Gold packs and rate their risks.

Products Assessed	 Marlboro Gold or VLN[™] (depending on condition) Comparator categories: conventional cigarettes, e-cigarettes, NRTs, snuff 			
Constructs Assessed	Perceived Risk of Addiction (6 items)		Perceived Health Risks (18 items)	
	 Examples: being addicted to being unable to quit having to use to feel better feeling like you have to use 		 Examples: lung cancer emphysema mouth/ throat cancer respiratory infection heart disease aging faster earlier death serious illness 	
Participants (<i>n</i> ≈ 29,000)	Adult Current SmokersIntending to QuitNot Intending to Quit	Adult Former SmokersPast-Year QuittersLong-Term Quitters		Never Smokers Young Adult (LA-25) Overall Adults

QUANTITATIVE RESEARCH ON UNDERSTANDING

Modified risk information about VLN[™] in online experiment:


VLN[™] Condition Marlboro Gold[™] Condition "A new tobacco product called VLN™ (Very Low Nicotine) is currently in development... VLN[™] cigarettes are Survey Wording made from a tobacco plant that has been altered to contain much lower levels of nicotine than the tobacco used in traditional cigarettes." Other conditions varied this wording: "Helps you smoke less" **"95% LESS NICOTINE"** "Helps reduce your urge to smoke" "Helps reduce your nicotine consumption" '... greatly reduces your nicotine consumption." Pack Labeling "Nicotine is addictive. Less nicotine does NOT mean safer. All cigarettes can cause disease and death."





PERCEIVED ADDICTION RISK






"Taking into consideration everything you know about [product], indicate what you believe is the <u>risk</u> of each of the following long-term or lifetime <u>addiction-related</u> issues because of [product]... being addicted to [product]."

Source: Based on the M/A/R/C Research Quantitative Report, p. 99. Error bars: 95% Cls.








"Taking into consideration everything you know about [product], indicate what you believe is the <u>risk</u> of each of the following long-term or lifetime <u>health-related</u> issues because of [product]."

Source: Based on the M/A/R/C Research Quantitative Report, p. 64. Error bars: 95% Cls.







"Taking into consideration everything you know about [product], indicate what you believe is the <u>risk</u> of each of the following long-term or lifetime <u>health-related</u> issues because of [product]."

Source: Based on the M/A/R/C Research Quantitative Report, p. 85. Error bars: 95% Cls.



- Possibility A: Participants assumed they would use VLN[™] cigarettes the same amount as other cigarettes when rating the products. Their health risk ratings are inaccurate.
- Possibility B: Participants assumed they would use less of VLN[™] cigarettes compared to other cigarettes when rating the products. Their health risk ratings are potentially accurate.





"If you were asked to describe VLN™ to a friend or family member, what would you say?"

Responses suggested a mix of understanding, uncertainty, and confusion; many were inconclusive.

Health risks remains the same but 95% less nicotine.

Low-nicotine cigarette. Like "regular" cigarettes with reduced nicotine levels. **NOT clear** whether risk levels are reduced at commensurate levels. It's a cigarette with 95% less nicotine so it gives you the **same feeling as smoking without all of the harmful effects**. Many people are addicted to the action of smoking as much as they are to the chemicals so it might be a better solution to try.


It is a cigarette with less nicotine.

Source: Example responses obtained from WA/R/C Research Quantitative Study raw data.





Four phases of <u>qualitative</u> consumer research also found mixed interpretations of VLN™'s health risks.



Some people understood the need to cut down or quit smoking to benefit from using VLN[™]. Others did not.

Source: Section VIIIE Scientific Studies and Analyses – Consumer Perception, pp. 3-26; Example quotes obtained from M/A/R/C Qualitative Study Phase 4 Transcripts.







Adults accurately perceive VLN[™] as less addictive than other cigarettes and similarly addictive as NRTs.

Adults perceive VLN[™] as moderately to very likely to cause tobacco-related diseases.



Adults perceive VLN[™] as less likely to cause diseases compared to other cigarettes.

It is unclear whether this is because they believe they will smoke fewer VLN[™] cigarettes.





Discuss whether the labeling enables consumers to accurately understand the following effects of using the products:

- Addiction risk
- Disease risks

REFERENCES



Bolliger, C. T. (2000). Practical experiences in smoking reduction and cessation. Addiction, 95, S19–S24.

Bolliger, C. T., Zellweger, J. P., Danielsson, T., van Biljon, X., Robidou, A., Westin, Å., ... & Säwe, U. (2002). Influence of long-term smoking reduction on health risk markers and quality of life. *Nicotine & Tobacco Research, 4*, 433-439.

Burchfiel, C. M., Marcus, E. B., Curb, J. D., MacLean, C. J., Vollmer, W. M., Johnson, L. R., ... & Buist, A. S. (1995). Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. American Journal of Respiratory and Critical Care Medicine, 151, 1778-1785.

Byron, M. J., Jeong, M., Abrams, D. B., & Brewer, N. T. (2018). Public misperception that very low nicotine cigarettes are less carcinogenic. *Tobacco Control, 27,* 712-714. Denlinger-Apte, R. L., Joel, D. L., Strasser, A. A., & Donny, E. C. (2017). Low nicotine content descriptors reduce perceived health risks and positive cigarette ratings in participants using very low nicotine content cigarettes. *Nicotine & Tobacco Research, 19,* 1149-1154.

Dermody, S. S., Donny, E. C., Hertsgaard, L. A., & Hatsukami, D. K. (2015). Greater reductions in nicotine exposure while smoking very low nicotine content cigarettes predict smoking cessation. *Tob Control, 24*(6), 536-539. doi:10.1136/tobaccocontrol-2014-051797

Donny, E. C., Denlinger, R. L., Tidey, J. W., Koopmeiners, J. S., Benowitz, N. L., Vandrey, R. G., . . . Hatsukami, D. K. (2015). Randomized trial of reduced-nicotine standards for cigarettes. *New England Journal of Medicine*, *373*(14), 1340-1349. doi:10.1056/NEJMsa1502403

Eliasson, B., Hjalmarson, A., Kruse, E., Landfeldt, B., & Westin, Å. (2001). Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine & Tobacco Research, 3, 249-255.

El-Toukhy, S., Baig, S. A., Jeong, M., Byron, J. M., Ribisl, K. M., Brewer, N. T. (2018). Impact of tobacco product claims of lower exposure and lower risk. Tobacco Control, 27, s62-s69.

Foulds, J., Hobkirk, A., Wasserman, E., Richie, J., Veldheer, S., Krebs, N. M., . . . Muscat, J. (2018). Estimation of compliance with exclusive smoking of very low nicotine content cigarettes using plasma cotinine. *Preventive Medicine*, *117*, 24-29. doi:10.1016/j.ypmed.2018.04.011

Godtfredsen, N. S., Holst, C., Prescott, E., Vestbo, J., & Osler, M. (2002). Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. *American Journal of Epidemiology*, *156*, 994-1001.

Godtfredsen, N. S., Osler, M., Vestbo, J., Andersen, I., & Prescott, E. (2003). Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. *Journal of Epidemiology and Community Health*, *57*(6), 412-416.

Godtfredsen, N. S., Prescott, E., & Osler, M. (2005). Effect of smoking reduction on lung cancer risk. Journal of the American Medical Association, 294, 1505-1510.

Hatsukami, D. K., Kotlyar, M., Allen, S., Jensen, J., Li, S., Le, C., & Murphy, S. (2005). Effects of cigarette reduction on cardiovascular risk factors and subjective measures. Chest, 128, 2528-2537.

Hatsukami, D. K., Kotlyar, M., Hertsgaard, L. A., Zhang, Y., Carmella, S. G., Jensen, J. A., . . . Hecht, S. S. (2010). Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. *Addiction*, *105*(2), 343-355. doi:10.1111/j.1360-0443.2009.02780.x

REFERENCES



Hatsukami, D. K., Hertsgaard, L. A., Vogel, R. I., Jensen, J. A., Murphy, S. E., Hecht, S. S., . . . Allen, S. S. (2013). Reduced nicotine content cigarettes and nicotine patch. Cancer Epidemiology, Biomarkers & Prevention, 22(6), 1015-1024. doi:10.1158/1055-9965.EPI-12-1439

Hatsukami, D. K., Luo, X., Jensen, J. A., al'Absi, M., Allen, S. S., Carmella, S. G., . . . Donny, E. C. (2018). Effect of immediate vs gradual reduction in nicotine content of cigarettes on biomarkers of smoke exposure: A randomized clinical trial. *JAMA*, *320*(9), 880-891. doi:10.1001/jama.2018.11473

Haustein, K. O., Krause, J., Haustein, H., Rasmussen, T., & Cort, N. (2004). Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT). *International Journal of Clinical Pharmacology and Therapeutics*, *42*(2), 83-92.

Higgins, S. T., Heil, S. H., Sigmon, S. C., Tidey, J. W., Gaalema, D. E., Hughes, J. R., ... Tursi, L. (2017). Addiction Potential of Cigarettes With Reduced Nicotine Content in Populations With Psychiatric Disorders and Other Vulnerabilities to Tobacco Addiction. JAMA Psychiatry, 74(10), 1056-1064. doi:10.1001/jamapsychiatry.2017.2355

Inoue-Choi, M., Hartge, P., Park, Y., Abnet, C. C., & Freedman, N. D. (2018). Association Between Reductions of Number of Cigarettes Smoked per Day and Mortality Among Older Adults in the United States. *American journal of epidemiology*, 188(2), 363-371.

Johnston, L. D., Miech, R. A., O'Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Patrick, M. E. (2019). Monitoring the Future national survey results on drug use 1975-2018: Overview, key findings on adolescent drug use. University of Michigan - Ann Arbor: Institute for Social Research.

O'Brien, E. K., Nguyen, A. B., Persoskie, A., & Hoffman, A. C. (2017). U.S. adults' addiction and harm beliefs about nicotine and low nicotine cigarettes. *Preventive Medicine, 96,* 94-100.

O'Connor, R. J., Ashare, R. L., Fix, B. V., Hawk, L. W., Cummings, K. M., & Schmidt, W. C. (2007). College students' expectancies for light cigarettes and potential reduced exposure products. *American Journal of Health Behavior*, *31*, 402-410.

Pacek, L. R., Vandrey, R., Dermody, S. S., Denlinger-Apte, R. L., Lemieux, A., Tidey, J. W., . . . Donny, E. C. (2016). Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use. *Drug and alcohol dependence, 167*, 228-232. doi:10.1016/j.drugalcdep.2016.08.620

Perkins, K. A., Karelitz, J. L., & Kunkle, N. (2018). Evaluation of menthol per se on acute perceptions and behavioral choice of cigarettes differing in nicotine content. *Journal of Psychopharmacology*, 32(3), 324-331.

Stein, M. D., Weinstock, M. C., Herman, D. S., & Anderson, B. J. (2005). Respiratory symptom relief related to reduction in cigarette use. Journal of General Internal Medicine, 20, 889-894.

Tidey, J. W., Pacek, L. R., Koopmeiners, J. S., Vandrey, R., Nardone, N., Drobes, D. J., ... Donny, E. C. (2017). Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms. *Nicotine & Tobacco Research*, *19*(1), 59-67. doi:10.1093/ntr/ntw199

Tverdal, A. and K. Bjartveit. (2006). Health consequences of reduced daily cigarette consumption. Tobacco Control, 15, 472-480.

Walker, N., Howe, C., Bullen, C., Grigg, M., Glover, M., McRobbie, H., . . . Whittaker, R. (2012). The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: A randomized controlled trial. *Addiction, 107*(10), 1857-1867. doi:10.1111/j.1360-0443.2012.03906.x

Walker, N., Fraser, T., Howe, C., Laugesen, M., Truman, P., Parag, V., . . . Bullen, C. (2015). Abrupt nicotine reduction as an endgame policy: A randomised trial. *Tobacco Control*, 24(e4), e251-257. doi:10.1136/tobaccocontrol-2014-051801





Discuss whether the labeling enables consumers to accurately understand the following effects of using the products:

- Addiction risk
- Disease risks

THE END



